Immunological Analysis of Lung Immunity Probiotic (GLB3)
by Marcus Antebi
Article at a Glance:
Immunological Analysis of Lung Immunity Probiotic (GLB3) by Marcus Antebi
There are friendly bacteria that are hard at work in your small and large intestines. This includes your colon. The friendly bacteria are cells. They reside in the digestive tract and they do not destroy other vital cells because they never cross through the intestinal walls.
Over millions of years these goods cells evolved to reside symbiotically with our immune system. They are competitive creatures. The competitive drive helped them to develop arsenals of chemical weapons that they use to destroy bad cells, also known as pathogens. That is why the good bacteria have a direct positive effect on our overall immune system. The chemical weapons that the good bacteria release do not harm other varieties of friendly bacteria.
Several things can wipe out or greatly reduce the numbers of good bacteria colonies. When the bacteria counts are too low, pathogens have an opportunity to overthrow the remaining bacteria or simply proliferate enough to create an illness in the host. Such common illnesses are yeast infections, irritable bowel syndrome, diarrhea, ulcers, depression, viruses, and common colds. Even obesity and cancer are scientifically linked to good bacteria deficiencies.
What knocks out the good bacteria? Well, if you had a perfect diet, no stress, there were no environmental factors, you never took antibiotics, and your genetic make up was perfect, then you would likely have the perfect balance of digestive bacteria throughout your entire life.
Generally, you should be able to repopulate the vital good families of bacteria through diet and just being alive. But oftentimes this is not enough. We have only recently discovered the true nature and behavior of good bacteria and its role in our overall health.
Lung Immunity Probiotic (Lactobacillus plantarum), colonizes the human gastrointestinal tract with a strong strain of bacteria in enough quantities (2.5 billion viable cells) of a plant-based bacteria that is clinically proven to survive the low pH of the stomach and make its way into the lower intestines. At that point, this family of Lactobacillus plantarum supports digestion and overall immunity.
The formulation in the Lung Immunity Probiotic shows a positive tendency towards eliminating common bacteria that cause complications in the lungs while first they reside in the intestines.* Additionally, the several polypeptides and polysaccharides contained in the formula help to "train" the immune system outside of the digestive system to identify and destroy these pathogens in the lungs, where they would otherwise cause damage.*
Part Two: Immunological Analysis of Lung Immunity Probiotic
The medium of the human body, especially our immune system, with all of its effector cells (macrophages, monocytes, NK, T-cells, B-cells, etc.) and molecules (cytokines, interleukins, etc.) with pathogenic microorganisms of different types, is susceptible to a wide variety of reactions. These reactions most often can be referred to as inflammatory immune responses and anti-inflammatory immune responses. Activated macrophages/monocytes are main sources of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in a lot of diseases.
TNF-α is secreted by activated T cells and stimulates the secretion of other pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and others. Classical anti-inflammatory cytokines that are immunosuppressive are IL-10, IL-4 and others. They are secreted by Th2 cells, B cells, and macrophages and have two very important functions; they inhibit cytokine synthesis and suppress the expression of major histocompatibility complex (MHC) class II molecules in antigen-presenting cells.*
Results and Discussion
The main ingredients of Lung Immunity Probiotic—a microbial lysate containing polypeptides and lipopolysaccharides and the probiotic strain Lactobacillus plantarum GLP3—were subjected to an in vitro immunological assay to complement existing data on probiotic bacteria and clinical assays on the complex of polypeptides and lipopolysaccharides (Maria Nikolova et al., 2009).
The results of the test demonstrated the lack of cytotoxicity of Lung Immunity Probiotic ingredients and their safety for use as a nutritional supplement.
Subsequent immunological tests demonstrated that Lung Immunity Probiotic did not lead to the synthesis of the inflammatory TNF-α and IL-6 molecules (inflammatory). The amount of synthesized proinflammatory immunological molecules was comparable in the control group of cells (macrophages) and in the same cells, but treated with Lung Immunity Probiotic. This indicates that the product would not induce a TNF-α mediated inflammatory immune response.*
With respect to another major interleukin, IL-6, which results in an inflammatory immune response, the results presented in Figure 2 indicate that the addition of the Lung Immunity Probiotic product again would not produce a negative reaction and inflammation.*
The results demonstrated the ability of the products to reduce the amount of IL-6 export that is synthesized by the macrophage control group (Figure 2). All data presented showed that the product did not provoke inflammation and had the potential to repress the inflammation.*
This ability of the products to modulate the inflammatory immune response provides a very good basis for its application in the fight against various pathogens that cause inflammation.*
Furthermore, a very good positive effect of Lung Immunity Probiotic has been demonstrated—namely the ability to largely retain the production of an important anti-inflammatory interleukin such as IL-10. From the results obtained from the tests of the product it is shown that it is able to induce the synthesis of a much smaller amount of IL-10 from splenocytes, compared with the control sample.
All these in vitro immunological results demonstrate the strong anti-inflammatory potential of the Lung Immunity Probiotic product. This, together with the results of clinical studies of the complex of polypeptides and lipopolysaccharides, which has been proven by Acad. Bogdan Petrunov and his team, can prepare our immune system to deal with secondary bacterial pneumonia (Maria Nikolova et al., 2009). As an additional effect, it leads to the formation of a specific immune response to the underlying bacteria that cause the development of pneumonia.
Maria Nikolova, Draganka Stankulova, Hristo Taskova, Plamen Nenkov, Vladimir Maximov, Bogdan Petrunov (2009), Polybacterial immunomodulator Respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections.
*All statements herein have not been evaluated by the Food and Drug Administration. The products on this website were not intended to diagnose, treat, cure, or prevent any disease.